Company intelligence / Profile preview

Attgeno AB

Solna, Stockholms län, Swedenattgeno.com ↗

Ownership: Private
Development stage: Other

Overview

Attgeno has developed Supernitro, a novel intravenous NO donor drug designed to reverse life-threatening high blood pressure in the lungs. A Phase IIa clinical trial was completed in spring 2024 on patients with acute pulmonary hypertension following cardiac surgery, involving 12 evaluable patients. The company is exploring additional indications where targeted NO delivery is beneficial[1].

Therapeutic areas: OtherCardiovascular
Modalities: Small molecules (specifically nitric oxide-donating drugs)[1][4][5]
Industry: Biotech

Drug pipeline

2 assets

PDNO

1 more asset in the full pipeline.

Partnerships

Partly financed by Sweden's Innovation Agency Vinnova[5]

Beyond the preview

Go deeper on Attgeno AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Attgeno AB.